News

FDA expands approval of Moderna's RSV vaccine to some adults under age 60
The FDA expanded its approval of Moderna's RSV vaccine on Thursday to include adults under age 60 at increased risk of the ...
US CDC official in charge of COVID, RSV data resigns ahead of vaccine meeting
A U.S. government scientist who oversees the team responsible for collecting data on COVID-19 and RSV hospitalizations used ...
STAT8d
FDA clears Moderna’s RSV vaccine for use in people aged 18 to 59
The FDA expanded the approval of Moderna’s RSV vaccine, extending the license to include more adults and giving the company a ...
Fierce Pharma12h
Adjusted ACIP agenda omits anticipated votes, revives talks on vaccine ingredient erroneously linked to autism
In the wake of Robert F. Kennedy Jr.’s abrupt revamp of the CDC’s Advisory Committee on Immunization Practices, details from the panel’s planned meeting next week are confirming many industry ...
Clinical Advisor3d
RSV Vaccine mResvia Approved for Adults Aged 18 to 59 at Increased Risk
For the 2025-2026 respiratory viral season, Moderna intends to have mResvia available for both FDA-approved patient populations.
Why a vaccine expert left the CDC: ‘Americans are going to die’
Dr. Fiona Havers, who studied medicine at the University of Washington, says the wholesale dismissal of the CDC's scientific ...
CIDRAP7d
Moderna receives expanded approval for RSV vaccine
The FDA approved mResvia for the prevention of RSV in people ages 18 to 59 years who are at increased risk for severe disease ...
FDA clears Moderna’s RSV vaccine for use in people ages 18 to 59
The Food and Drug Administration expanded the approval of Moderna’s RSV vaccine on Thursday, extending the license to include ...
The Manila Times3d
Clover Initiates Phase I Clinical Trial for RSV + hMPV ± PIV3 Respiratory Combination Vaccine Candidates
Potential First-in-Class Respiratory Combination Vaccine Candidates SCB-1022 (RSV + hMPV) and SCB-1033 (RSV + hMPV + PIV3) Enter the Clinical Trial Stage -- ...